MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Phase 1
Terminated
Conditions
Leukemia
Lymphoma
Myeloma
Interventions
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Radiation: Radiation Treatment
Procedure: Stem Cell Transplantation (SCT)
Drug: Sirolimus
Procedure: Anti-third Party Cytolytic T-lymphocytes (CTL)
First Posted Date
2007-05-15
Last Posted Date
2011-12-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT00473551
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Phase 1
Completed
Conditions
Richter's Transformation
Leukemia
Interventions
First Posted Date
2007-05-14
Last Posted Date
2013-11-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
92
Registration Number
NCT00472849
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

Phase 2
Conditions
Graft Failure
Interventions
Procedure: Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors
Drug: fludarabine
Procedure: TBI
First Posted Date
2007-05-11
Last Posted Date
2014-06-30
Lead Sponsor
Colorado Blood Cancer Institute
Target Recruit Count
20
Registration Number
NCT00472329
Locations
🇺🇸

Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States

IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Phase 3
Completed
Conditions
Myelodysplastic Syndrome
Leukemia
Acute Myeloid Leukemia
Interventions
First Posted Date
2007-05-04
Last Posted Date
2021-01-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
233
Registration Number
NCT00469144
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Interventions
First Posted Date
2007-05-04
Last Posted Date
2021-01-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
72
Registration Number
NCT00469014
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: Fludarabine
Drug: Campath
Procedure: Transplant
First Posted Date
2007-04-19
Last Posted Date
2013-09-06
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
86
Registration Number
NCT00462332
Locations
🇮🇹

ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy

🇮🇹

Ospedale Regionale A. Pugliese, Catanzaro, Italy

🇮🇹

Universita di Ferrara, Ferrara, Italy

and more 20 locations

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Phase 2
Completed
Conditions
Dyskeratosis Congenita
Aplastic Anemia
Interventions
Drug: Campath 1H
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Total Body Irradiation
Procedure: Stem Cell Transplantation
Drug: antithymocyte globulin
Drug: Methylprednisolone
First Posted Date
2007-04-03
Last Posted Date
2017-12-05
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
36
Registration Number
NCT00455312
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2007-03-30
Last Posted Date
2013-08-26
Lead Sponsor
The University of New South Wales
Target Recruit Count
2000
Registration Number
NCT00454480
Locations
🇬🇧

Queen's Hospital, Burton-upon-Trent, England, United Kingdom

🇬🇧

Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom

🇬🇧

Hereford Hospitals, Hereford, United Kingdom

and more 93 locations

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Phase 2
Completed
Conditions
Acute Myeloid Leukemia in Remission
de Novo Myelodysplastic Syndrome
Fanconi Anemia
Previously Treated Myelodysplastic Syndrome
Interventions
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total-Body Irradiation
First Posted Date
2007-03-28
Last Posted Date
2020-01-29
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
6
Registration Number
NCT00453388
Locations
🇺🇸

Children's Hospital and Research Center at Oakland, Oakland, California, United States

🇺🇸

Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 2 locations

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Phase 1
Completed
Conditions
Leukemia
Interventions
First Posted Date
2007-03-27
Last Posted Date
2011-11-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
48
Registration Number
NCT00452374
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of California-San Diego, La Jolla, California, United States

© Copyright 2025. All Rights Reserved by MedPath